by In2Pharma | Feb 16, 2022 | News
The Netherlands Medicinal Product Quality Defects and Shortages on the Dutch Market should be reported through the “Meldpunt geneesmiddelentekorten en -defecten”. As of 01 January 2022, the Medicines Evaluation Board (MEB) and the Inspectorate (IGJ) have implemented...
by In2Pharma | Feb 16, 2022 | News
The Netherlands The Medicines Evaluation Board (MEB) increases the fee rates for authorisation applications, authorisation changes and the annual fees of human medicinal products. Fees for consultation procedures will also be increased. Fees for veterinary will remain...
by In2Pharma | Oct 26, 2021 | News
The Netherlands The reporting form of the Medicine Shortages and Defects Reporting Center has been made more user-friendly. Some questions were deleted (e.g. address details of the company), textual changes were done, some questions were added and changes to the...
by In2Pharma | Jul 31, 2020 | News
The Netherlands The Claims Regulation has been in force since 2012. All Member States submitted claims for botanicals (herbals) and non-botanicals (vitamins and minerals). These have been scientifically assessed by EFSA and subsequently endorsed by the European...
by In2Pharma | Jul 7, 2020 | News
The Netherlands On the basis of scientific conditions, the Medicines Evaluation Board (MEB) will draw up a list of medicines for which switching is undesirable. It will do this in the interests of patient safety. Medicines with the same active ingredient, dosage and...
